20 results on '"Kahatt, C."'
Search Results
2. Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer
3. Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study
4. 1790P Phase II data of lurbinectedin (LUR) and irinotecan (IRI) in relapsed small cell lung cancer (SCLC) patients (pts) with chemotherapy-free interval (CTFI)>30 days (d)
5. 641P Phase I/II clinical and pharmacokinetic study of ecubectedin in combination with irinotecan in patients with selected advanced solid tumors
6. Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer
7. 679P Lurbinectedin (LRB) pharmacokinetics (PK) and safety when co-administered with itraconazole (ITZ) in patients with advanced solid tumor
8. 671P Safety and efficacy of PM060184 plus gemcitabine in advanced solid tumors
9. 1784P Activity of lurbinectedin in second-line SCLC patients candidates for platinum re-challenge
10. 551P Phase I study of lurbinectedin in Japanese patients with pretreated advanced tumours: Final results
11. Lurbinectedin (LUR) in combination with irinotecan (IRI) in patients (pts) with advanced solid tumours
12. Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial
13. Activity of lurbinectedin as single agent and in combination in patients with advanced small cell lung cancer (SCLC)
14. 471P - Lurbinectedin (LUR) in combination with irinotecan (IRI) in patients (pts) with advanced solid tumours
15. Anti-tumor activity of PM01183 (lurbinectedin) in BRCA1/2-associated metastatic breast cancer patients: results of a single-agent phase II trial
16. 932O - Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial
17. 1529PD - Activity of lurbinectedin as single agent and in combination in patients with advanced small cell lung cancer (SCLC)
18. 223O - Anti-tumor activity of PM01183 (lurbinectedin) in BRCA1/2-associated metastatic breast cancer patients: results of a single-agent phase II trial
19. Lurbinectedin (PM01183) Activity in Platinum-Resistant/Refractory Ovarian Cancer Patients. Preliminary Results of an Ongoing Two-Stage Phase II Study
20. 968O - Lurbinectedin (PM01183) Activity in Platinum-Resistant/Refractory Ovarian Cancer Patients. Preliminary Results of an Ongoing Two-Stage Phase II Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.